Pharmaceuticals News and Research

RSS

Pharmaceutical manufacturers to provide 50% discount on brand-name prescription drugs

Vice President Joe Biden, the U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services (CMS) today announced that the nation's pharmaceutical manufacturers will provide 50 percent discounts on the cost of covered brand-name prescription drugs for beneficiaries in the Medicare Part D coverage gap, or donut hole, starting in 2011.

24 Sep 2010

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of a study "Percutaneous Tibial Nerve Stimulation Effects on Detrusor Overactivity Incontinence Are Not Due to a Placebo Effect A Randomized, Double-Blind, Placebo Controlled Trial," to be published in the November 2010 print edition of THE JOURNAL OF UROLOGY.

24 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

New EID/Qb technique offers real-time monitoring of AVF function during dialysis

A simple equation provides real-time feedback to detect access recirculation in arteriovenous fistulas (AVFs) during hemodialysis, reports a study in the September/October issue of ASAIO Journal, Official Journal of the American Society of Artificial Internal Organs.

24 Sep 2010

PAREXEL Consulting releases two new white papers on biosimilar development

PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.

From Parexel 24 Sep 2010

Belfer Institute, sanofi-aventis collaborate to discover anticancer drugs

Dana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis announced today that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targets and related biomarkers.

24 Sep 2010

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.

24 Sep 2010

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

NeoStem, Inc. an international biopharmaceutical company with operations in the U.S. and China and Progenitor Cell Therapy, LLC a privately held cell therapy company that serves the cell therapy industry from licensed, state-of-the art cell therapy manufacturing facilities in New Jersey and California today jointly announced the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.

24 Sep 2010

FDA grants clearance for HPβCD treatment for Niemann Pick Type C disease

Children's Hospital & Research Center Oakland announced today that the US Food and Drug Administration (FDA) has granted clearance of an Investigational New Drug (IND) application to introduce Trappsol Cyclo (Hydroxypropyl Beta Cyclodextrin or HPβCD) into the brains of six year old identical twin girls dying of a rare brain-destroying cholesterol disease called Niemann Pick Type C (NPC).

24 Sep 2010

BioSeek signs two-year agreement with Cellzome

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year agreement with Cellzome.

24 Sep 2010

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010.

24 Sep 2010

Cardialysis and Sticares InterACT announce strategic collaboration

Cardialysis and Sticares InterACT, both Contract Research Organizations (CROs) headquartered in The Netherlands, announced today that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine. Both organizations have substantial experience and success in the execution of clinical research projects for pharmaceutical, biotechnology and medical device companies.

23 Sep 2010

Arrowhead increases ownership in Calando Pharmaceuticals through Series A Preferred Stock exchange

Arrowhead Research Corporation today announced that it has increased its ownership of majority owned subsidiary Calando Pharmaceuticals through the exchange of Calando Series A Preferred Stock for Arrowhead warrants.

23 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

PharmacoEconomics releases special issue on CER

Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that the Adis journal PharmacoEconomics has released a special issue devoted entirely to comparative effectiveness research (CER).

23 Sep 2010

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.

23 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics' Clean Genome E. coli. Financial details of the contract were not disclosed.

23 Sep 2010

Pharmaceuticals News and Research

Pharmaceutical manufacturers to provide 50% discount on brand-name prescription drugs

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

New EID/Qb technique offers real-time monitoring of AVF function during dialysis

PAREXEL Consulting releases two new white papers on biosimilar development

Belfer Institute, sanofi-aventis collaborate to discover anticancer drugs

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

FDA grants clearance for HPβCD treatment for Niemann Pick Type C disease

BioSeek signs two-year agreement with Cellzome

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Cardialysis and Sticares InterACT announce strategic collaboration

Arrowhead increases ownership in Calando Pharmaceuticals through Series A Preferred Stock exchange

Tolerx presents otelixizumab preclinical research at 46th EASD

PharmacoEconomics releases special issue on CER

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

Athersys presents MultiStem phase I study results at TCT Conference

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence